| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/16/2011 | US20110142850 Method of treating cd40-mediated diseases |
| 06/16/2011 | US20110142849 Pcsk9 antagonists |
| 06/16/2011 | US20110142848 Anti-beta-2-microglobulin agents and the use thereof |
| 06/16/2011 | US20110142847 Methods of Eliciting Broadly Neutralizing Antibodies Targeting HIV-1 GP41 |
| 06/16/2011 | US20110142846 Method for diagnosing and treating emphysema |
| 06/16/2011 | US20110142845 NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE NOGO-66 RECEPTOR (NgR) AND USES THEREOF |
| 06/16/2011 | US20110142844 Anti-Extended Type I Glycosphingolipid Antibody, Derivatives Thereof And Use |
| 06/16/2011 | US20110142843 Fetal polypeptides from human liver |
| 06/16/2011 | US20110142842 Polypeptides |
| 06/16/2011 | US20110142841 Compositions and methods for the treatment of systemic lupus erythematosis |
| 06/16/2011 | US20110142840 Compositions and Methods for Diagnosing and Treating Cancer |
| 06/16/2011 | US20110142839 Treatment of pulmonary edema |
| 06/16/2011 | US20110142838 Novel antibodies against cancer target block tumor growth, angiogenesis and metastatis |
| 06/16/2011 | US20110142837 Method Of Treating Acute Respiratory Distress Syndrome |
| 06/16/2011 | US20110142836 B-cell depleting agents for the treatment of chronic fatigue syndrome |
| 06/16/2011 | US20110142835 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| 06/16/2011 | US20110142834 Treatment of hearing and balance impairments using compounds having erythropoietin activity |
| 06/16/2011 | US20110142833 Methods for treating and preventing fibrosis |
| 06/16/2011 | US20110142832 Soluble tumor necrosis factor receptor treatment of medical disorders |
| 06/16/2011 | US20110142831 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease |
| 06/16/2011 | US20110142830 Modulation of the trpv: vps10p receptor system for the treatment of pain |
| 06/16/2011 | US20110142829 Anti-tumour compositions and methods |
| 06/16/2011 | US20110142828 Treatment prediction involving hmgcr |
| 06/16/2011 | US20110142827 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| 06/16/2011 | US20110142826 Azaindolizines and methods of use |
| 06/16/2011 | US20110142825 Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity |
| 06/16/2011 | US20110142824 Antibodies Against Amyloid-Beta Peptide |
| 06/16/2011 | US20110142823 Humanized antibodies that recognize beta amyloid peptide |
| 06/16/2011 | US20110142822 Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof |
| 06/16/2011 | US20110142821 Roles for dual endothelin-1/angiotensin ii receptor (dear) in hypertension and angiogenesis |
| 06/16/2011 | US20110142820 Novel Targets for Regulation of Angiogenesis |
| 06/16/2011 | US20110142794 Methods and Compositions to Determine the Chemosensitizing Dose of Suramin Used in Combination Therapy |
| 06/16/2011 | US20110142792 Compositions for Increasing Polypeptide Stability and Activity, and Related Methods |
| 06/16/2011 | US20110142791 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| 06/16/2011 | US20110142763 Megalin-Based Delivery of Therapeutic Compounds to the Brain and Other Tissues |
| 06/16/2011 | US20110142761 Il-1 binding proteins |
| 06/16/2011 | US20110142756 Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Precipitates In The Cancer |
| 06/16/2011 | US20110138888 Treatment of obesity |
| 06/16/2011 | CA2785996A1 Sr-bi as a predictor of human female infertility and responsiveness to treatment |
| 06/16/2011 | CA2783968A1 Immunogens, process for preparation and use in systems of polyclonal antibodies production |
| 06/16/2011 | CA2783740A1 Monoclonal antibodies that bind b7h6 and uses thereof |
| 06/16/2011 | CA2783691A1 Anti-inflammatory agents directed against citrullinated epitopes |
| 06/16/2011 | CA2783678A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | CA2783654A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | CA2783651A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | CA2783610A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | CA2783563A1 Anti-inflammatory antibodies and uses therefor |
| 06/16/2011 | CA2783514A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | CA2783513A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | CA2783338A1 Anti-c4.4a antibodies and uses thereof |
| 06/16/2011 | CA2782420A1 Human antigen binding proteins that bind .beta.-klotho, fgf receptors and complexes thereof |
| 06/16/2011 | CA2782132A1 Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant |
| 06/16/2011 | CA2781311A1 Methods for enhancing anti-tumor antibody therapy |
| 06/16/2011 | CA2781050A1 Pcsk9 antagonists |
| 06/16/2011 | CA2780069A1 Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| 06/15/2011 | EP2333114A1 S. pneumoniae antigens |
| 06/15/2011 | EP2333091A2 Vectors and methods for genetic immunization |
| 06/15/2011 | EP2333065A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| 06/15/2011 | EP2333064A1 Nucleotide and protein sequences of Nogo genes and methods based thereon |
| 06/15/2011 | EP2332995A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/15/2011 | EP2332993A1 Human monoclonal antibody to the human epidermal growth factor receptor |
| 06/15/2011 | EP2332991A2 Humanized anti-cd4 antibody with immunosuppressive properties |
| 06/15/2011 | EP2332990A1 Human anti-epidermal growth factor receptor antibody |
| 06/15/2011 | EP2332987A1 Anti-inflammatory agents directed against citrullinated epitopes |
| 06/15/2011 | EP2332983A2 Identification of tumor-associated cell-surface antigens for diagnosis and theapy |
| 06/15/2011 | EP2332981A2 Identification of tumor-associated cell-surface antigens for diagnosis and theapy |
| 06/15/2011 | EP2332980A2 Identification of tumor-associated cell-surface antigens for diagnosis and theapy |
| 06/15/2011 | EP2332979A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 06/15/2011 | EP2332978A1 Novel polypeptides involved in immune response |
| 06/15/2011 | EP2332976A1 Novel polypeptides involved in immune response |
| 06/15/2011 | EP2332973A2 Differential in tumour gene products and use of same |
| 06/15/2011 | EP2332961A2 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 06/15/2011 | EP2332581A1 Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine |
| 06/15/2011 | EP2332579A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 06/15/2011 | EP2332578A1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 06/15/2011 | EP2332577A1 Novel use of IL-1beta compounds |
| 06/15/2011 | EP2332576A1 Immunotherapy of B-cell malignancies using anti-CD22 antibody conjugates |
| 06/15/2011 | EP2332575A1 Treatment of cancer with novel anti-IL 13 monoclonal antibodies |
| 06/15/2011 | EP2332574A1 HCV NS3/4A Sequences |
| 06/15/2011 | EP2332573A1 Chimeric alphavirus replicon particles |
| 06/15/2011 | EP2332572A1 Nucleic acid vaccines for prevention of Flavivirus |
| 06/15/2011 | EP2332571A1 Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis |
| 06/15/2011 | EP2332570A1 Compositions and methods for treating neurological disorders |
| 06/15/2011 | EP2332569A2 Compositions and methods for treating neurological disorders |
| 06/15/2011 | EP2332565A1 Low dose methods for treating disorders in which TNFalpha activity is detrimental |
| 06/15/2011 | EP2332561A1 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| 06/15/2011 | EP2332408A1 Treating neurological disorders |
| 06/15/2011 | EP2331682A1 Infectious bronchitis vaccines derived from ib-qx-like strains |
| 06/15/2011 | EP2331578A1 Novel compositons and methods for treating ige-mediated disorders |
| 06/15/2011 | EP2331576A1 Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers |
| 06/15/2011 | EP2331574A2 Antibodies with mannose binding lectin effector function for inhibiting pathologic inflammatory conditions |
| 06/15/2011 | EP2331573A1 Hepatitis c antibodies and uses thereof |
| 06/15/2011 | EP2331565A2 Hiv-1 envelope polypeptides for hiv vaccine |
| 06/15/2011 | EP2331562A2 Peptides presenting an epitope of an a domain of factor h binding protein and methods of use |
| 06/15/2011 | EP2331142A2 Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells |
| 06/15/2011 | EP2331136A2 Frizzled-binding agents and uses thereof |
| 06/15/2011 | EP2331135A1 Methods of treating and preventing glucose toxicity |
| 06/15/2011 | EP2331134A2 Anti-pancreatic cancer antibodies |
| 06/15/2011 | EP2331133A2 Anti-lipid antibodies |
| 06/15/2011 | EP2331132A2 Methods for treating progressive multiple sclerosis |